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furthermore prolonged the latency to epithelial ulceration 
and reduced ulcer duration. Proliferation measurements with 
BrdU did not show any substantial effects of DS. The 
adherens junction protein β-catenin did significantly increase 
during irradiation, which occurred earlier with additional DS 
treatment. The hypoxia markers HIF-1α and GLUT-1 showed a 
progressive increase during irradiaton alone, which, however, 
was also not influenced by DS. IL-1β and NF-κB as markers of 
inflammation were dramatically increased during irradiation. 
While DS treatment abolished the radiation-induced increase 
of IL-1β, however, no systematical effect on the expression 
of NF-κB was observed.  
 
Conclusion: DS has a significant mucoprotective effect. This 
is not based on stimulation of epithelial proliferation nor on 
modulation of radiation-induced hypoxic changes. In 
contrast, reduced or modulated inflammatory processes 
and/or increased/modified function of adherens junctions 
may have a mechanistic role. This hypothesis, however, 
needs to be validated in further studies. 
 
Electronic Poster: Radiobiology track: Biomarkers and 
biological imaging  
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Purpose or Objective: Anticancer treatment affects 
composition and concentrations of metabolites in body fluids. 
In case of head and neck (HNC) cancers the acute radiation 
syndrome (ARS) was studied only at the genomic, proteomic 
and lipidomic levels. We aimed to identify and investigate 
molecular processes of treatment toxicity in HNC patients 
using high resolution NMR and NMR-based metabolomics. 
 
Material and Methods: Forty five patients with HNC were 
treated with radiotherapy (RT) or cisplatin-based 
chemoradiotherapy (CHRT). Blood samples were collected 
within a week after RT/CHRT completion. The ARS was 
evaluated using Multi-parameter Monitoring (MPM) – an 
original evaluation system designed by the study 
investigators. The patients were divided into two classes (of 
high and low ARS) on the basis of the highest individual ARS 
value observed during the treatment. The NMR spectra of the 
serum samples were acquired on 400.13 MHz Bruker 
spectrometer at 310 K. The referenced to alanine and 
bucketed to 0.002 ppm spectra were analyzed using principal 
component analysis (PCA) and orthogonal partial least 
squares discriminant analysis (OPLS-DA). Additional statistical 
analyses (Mann-Whittney test, Pearson correlation) were 
performed on quantified metabolites. 
 
Results: In the high ARS group we observed the increased 
signals of N-acetyl-glycoprotein – the NMR marker of 
inflammation, and acetate – a product of beta-oxidation of 
adipose tissue fatty acids. The high ARS group showed also 
the decreased signals of metabolites involved in energy 
metabolism: branched chain amino acids (BCAAs), alanine, 
creatinine, carnitine and glucose as well as decreased choline 
containing compounds reflecting disturbed membrane 
metabolism. Furthermore, we observed the positive 
correlations between C-reactive protein (CRP) and N-acetyl-
glycoprotein as well as acetate and a percentage weight loss 
during the treatment. CRP was also negatively correlated 
with alanine and BCAAs. 
 
Conclusion: 1H NMR is an efficient tool for detection of 
RT/CHRT toxicity markers in human serum. The results 
indicate at least three concomitant processes related to high 
treatment toxicity (high ARS): inflammation, altered energy 
metabolism and disturbed membrane metabolism. The 
combination of clinical and molecular approaches could 
deliver comprehensive information on treatment response, 
allowing monitoring and/or prediction of tolerance/toxicity 
of therapy as well as its outcome. Such approach gives a step 
forward into personalized therapy. 
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Purpose or Objective: Cytokines, which are involved in 
chronic inflammation, are also related to tumor 
aggressiveness and resistance to treatment in many cancers. 
However, there are limited reports on the significance of 
cytokines in tumor response to radiotherapy (RT). The aim of 
this study was to analyze serum cytokine levels and identify 
their association with treatment outcome in patients with 
hepatocellular carcinoma (HCC) treated with RT. 
 
Material and Methods: Patients with HCC who treated with 
RT were eligible for this prospective study. Blood samples 
were collected before and after completion of the whole RT 
course. Serum cytokine levels measured using Cytokine Bead 
Array kits were analyzed with respect to patients’ clinical 
profiles and treatment responses. 
 
Results: Between September 2008 and October 2009, 51 
patients were included in the analysis. Median follow-up 
duration was 12.3 months (range, 0.5-62.3). Forty-seven 
patients were diagnosed with modified UICC stage III or IV 
disease at the time of RT. Baseline serum IL-8 level increased 
with increasing stage and the IL-6 level was highest in 
patients with a history of pre-RT treatment (treatment-non-
naïve). A higher baseline serum IL-6 level was also observed 
in patients with treatment failure, including overall, infield, 
and outfield failure, than in those without treatment failure. 
In subgroup analysis, a significant difference in serum IL-6 
level was observed only in treatment-non-naïve versus 
treatment-naïve patients. Median overall survival and 
progression-free survival (PFS) were 13.9 and 7.7 months, 
respectively. Elevated serum IL-6 level was significantly 
associated with PFS for patients with infield failure (HR 
1.011, p<0.0001). 
 
Conclusion: The current findings suggest that assessment of 
baseline serum IL-6 level may be helpful to predict treatment 
outcome after RT for HCC, especially in patients who undergo 
treatment before RT. 
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Purpose or Objective: Neoadjuvant radiotherapy (NeoRT) 
improves tumor local control and tumor resection in many 
cancers. The timing between the end of the NeoRT and 
surgery is driven by the occurrence of side effects or the 
tumor downsizing. Some studies demonstrated that the 
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timing of surgery and the RT schedule could influence tumor 
dissemination and subsequently patient overall survival. We 
demonstrated the impact of NeoRT on metastatic spreading 
in a Scid mice model. After an irradiation of 2x5gy, we show 
more metastasis in the lung when the mice are operated at 
day 4 compared to day 11 (1). Here, our aim is to evaluate 
with functional MRI (fMRI) the impact of the radiation 
treatment on the tumor microenvironment and subsequently 
to identify non-invasive markers helping to determine the 
best timing to perform surgery for avoiding tumor spreading. 
 
Material and Methods: We used two models of NeoRT in mice 
we have previously developed: MDA-MB 231 and 4T1 cells 
implanted in the flank of mice (1). When tumors reached the 
planned volume, they are irradiated with 2x5 Gy and then 
surgically removed at different time points after RT. 
Diffusion Weighted (DW) -MRI was performed every 2 days 
between RT and surgery. For each tumors we acquired 8 
slices of 1 mm thickness and 0.5 mm gap with an “in plane 
voxel resolution” of 0.5 mm. For DW-MRI, we performed 
FSEMS (Fast Spin Echo MultiSlice) sequences, with 9 different 
B-value (from 40 to 1000) and B0, in the 3 main directions. 
We also performed IVIM (IntraVoxel Incoherent Motion) 
analysis, in the aim to obtain information on intravascular 
diffusion, related to perfusion (F: perfusion factor) and 
subsequently tumor vessels perfusion.  
 
Results: With the MBA-MB 231 we observed a significant 
increase of F at day 6 after irradiation than a decrease and 
stabilization until surgery. No other modifications of the MRI 
signal, ADC, D or D* were observed. We observed similar 
results with 4T1 cells, F increased at day 3 than returned to 
initial signal (fig 1). The difference in the peak of F can be 
related to the difference in tumor growth between MBA-MB 
231 in four weeks and 4T1 in one week. 
 
 
Figure 1: Graphs representing F factor in tumor bearing mice 
before and after radiotherapy in MDA-MB 231(n=6) (Scid 
model) and in 4T1 (n=4) (BalbC model); (*=p<0, 05)  
 
Conclusion: For the first time, we demonstrate the 
feasibility of repetitive fMRI imaging in mice models after 
NeoRT. With these models, we show a significant difference 
between the pre-irradiated acquisition and day 6 or day 3 for 
perfusion F. This change occurs between the two previous 
time points of surgery demonstrating a difference in the 
metastatic spreading (1). These results are very promising for 
identifying noninvasive markers for guiding the best timing 
for surgery.  
Reference: (1) The timing of surgery after neoadjuvant 
radiotherapy influences tumor dissemination in a preclinical 
model Natacha Leroi et al. (2015) Oncotarget vol. 5 
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Purpose or Objective: To assess whether texture analysis of 
images obtained with Dual Energy CT (DECT) is related to 
KRAS and Ki-67 lung cancer biomarkers.  
 
Material and Methods: A retrospective review (May 2013 - 
January 2015) of 125 lung cancer patients with lung GSI 
(Gemstone Spectral Imaging) and perfusion CT imaging on a 
DECT was fulfilled. For 25 of them, the fraction of Ki-67 
positive-tumour cells was analysed and for 19 patients KRAS-
positive (mutation detected) or KRAS-negative (mutation not 
detected) character was evaluated (11 positive, 8 negative). 
DECT examination was performed on a Discovery CT 750 HD 
scanner (GE Healthcare, USA).  
For the perfusion exam, blood volume, blood flow and 
permeability-surface studies were analyzed. At GSI exam, 
images related to absorption in Hounsfield units (HU), iodine 
concentration and monochromatic virtual images 
reconstructed at 40, 60, 80, 100, 120 and 140 keV were 
assessed. Tumour fractal dimension was measured with the 
use of Mapfractalcount plug-in for ImageJ (National Institute 
of Health, USA) software.  
After extraction of DNA from paraffin embedded tissue using 
QIAamp DNA Investigator Kit (Qiagen), analysis of the KRAS 
gene exons 2 (codons 12/13) and 3 (codon 61) were 
performed in order to identify possible associated mutations 
with real-time PCR kit cOBAS® KRAS Mutation Test (Roche 
Diagnostics, SL).  
T-Student test or U Mann-Whitney test were used to compare 
differences between KRAS-positive from KRAS-negative 
cohorts. Pearson correlation coefficient was used to study 
linear relationship between fractal dimension and the 
fraction of Ki-67 positive-tumour cells.  
 
Results: Best result (p=0.02) for distinguishing KRAS-positive 
cohort was obtained for lesion fractal dimension at 140 keV 
virtual image. This parameter showed an AUC=0.80. It was 
predictive of KRAS-positive with 90.9% sensitivity and 75.0% 
specificity for a fractal dimension threshold of 2.352.  
There was a correlation of lesion fractal dimension in blood 
volume image and the fraction of Ki-67 positive-tumour cells 
(p= 0.04).  
 
 
 
Conclusion: Ki-67 positive-tumour cells and KRAS-positive 
biomarkers lead to tumour heterogeneity that modify 
radiographic image. Fractal dimension parameter quantifies 
such imaging heterogeneity and could allow to differentiate 
them.  
A higher fractal dimension (higher heterogeneity) of lesion at 
virtual monochromatic images is measured for KRAS-positive 
mutation, while a higher fraction of Ki-67 positive-tumour 
cells is associated with a more homogeneous blood volume at 
perfusion.  
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